Smaller biotech outran large-cap healthcare: XBI +2.9%, BBC +4.4% and NBI +1.9% against XLV (0.1%) and S&P health care (0.2%). Company news before the close included Artiva halting AlloNK after two trial deaths (Tue morning) and Pfizer's MagnetisMM-32 myeloma win (06:45 ET).

Chips led a tech rebound: SOX +3.6% with all 30 members higher, Nasdaq Composite +1.2%, NDX +1.3%, S&P +0.6% and RUT +1.2%, while the Dow finished flat (+0.03%) as Boeing fell about 10% on a delivery-target cut. Brent settled (1.7%) at $113.88 on reports Iran discussed terms to end hostilities, October consumer confidence (10:00 ET) jumped to 91.7 vs 81 expected, and the 10Y held just under 5% into today's FOMC decision.

Artiva discontinued AlloNK (AB-101), its allogeneic NK cell therapy given with rituximab in rheumatoid arthritis and other B-cell-driven autoimmune diseases, after two Grade 5 events in its Phase 2a basket trial. It is cutting ~94% of staff and has hired Leerink to run a strategic review, with ~$319.1M in cash at 30 September.

Why it matters: Only one death was linked to treatment, and investigators tied it to fludarabine neurotoxicity from the cy/flu lymphodepletion, not the NK cells; the second, a sudden death two months after dosing, was judged unrelated with cause undetermined. That moves the read-through onto the conditioning regimen most autoimmune cell therapies borrowed from oncology, days after BMS disclosed a death in its zola-cel MS trial. The kill shot was durability: longer follow-up did not hold responses, which removes the case that a lighter, one-time NK approach could match CAR-T. With $319.1M in cash and no pipeline, ARTV is now a cash shell, and Leerink's mandate runs from reverse merger to liquidation.

Source: Endpoints

More: STAT; Fierce Biotech; BioSpace

MagnetisMM-32 (n=523) met its BICR-assessed PFS primary endpoint at a prespecified interim: Elrexfio monotherapy beat investigator's choice of EloPd, PVd or Kd in relapsed/refractory myeloma after prior anti-CD38 and lenalidomide. Estimated 18-month PFS was 68%, median not reached, OS immature; Pfizer will file with global regulators.

Why it matters: US accelerated approval sits at four or more prior lines, and MagnetisMM-32 tests it after a single line containing anti-CD38 and lenalidomide, where most patients now relapse. It is the second Phase 3 win after MagnetisMM-5 in double-class-exposed patients (topline April), giving Pfizer two confirmatory legs. The gaps are the ones that set share: no hazard ratio, no comparator PFS rate, and Grade 3+ infections of 27.5% vs 18.1% despite upfront prophylaxis. J&J's Tecvayli and Talvey and CAR-T already compete for these patients, so off-the-shelf monotherapy stepping down to monthly dosing is the pitch. Wait for the hazard ratio before modelling share.

Source: Fierce Pharma

More: Pfizer

Ferring agreed to buy Gameto, developer of Fertilo, stem cell-derived ovarian support cells that mature eggs outside the body to cut IVF hormone stimulation, for up to $1.3825B including development, regulatory and sales milestones; the upfront was not disclosed. Fertilo is cleared in Australia and parts of Latin America and is in US Phase 3.

Why it matters: Gameto raised $127M since 2020, most recently a $44M Series C in August 2025 led by Overwater with RA Capital, Insight and Two Sigma, so even a modest upfront makes this one of the cleaner venture exits in women's health this year. Ferring is private and already sells the hormone side of IVF; a technology that compresses stimulation to as little as three days would eat into that volume, so the buy is defensive as much as growth. Withholding the upfront in a milestone-heavy structure says the value rides on the US Phase 3, where Gameto guided to an interim readout in late 2026, and on an FDA path for a cell-based IVF product.

Source: Endpoints

More: BioPharma Dive

FDA issued draft guidance letting some individualized gene-editing therapies update within an approved "feature space" without a new BLA. — STAT

Novartis took a $1.9B impairment on Avidity's del-desiran but raised 2026 core operating income guidance to low-single-digit growth; Q3 sales rose 4% cc to $14.5B and it lifted Rhapsido's peak-sales target to $8B. — Fierce Biotech

A New Jersey federal judge denied Novo's preliminary injunction against Lilly's Zepbound and Mounjaro dose-comparison ads, finding at most a negligible sales impact; Novo's July suit continues. — Endpoints

GSK and Hansoh's B7-H3 ADC risvutatug rezetecan cut the risk of progression or death 67% in a China Phase 3 in relapsed osteosarcoma. — Fierce Biotech

Vanda said Nereus cut GLP-1-related vomiting 27% in Wegovy patients in a Phase 3 study and is eyeing a nausea indication. — Fierce Pharma

The EU approved AstraZeneca and Daiichi Sankyo's Enhertu as adjuvant therapy for HER2-positive early breast cancer with residual disease after neoadjuvant treatment. — PR

The US renewed a $270M supply contract for Regeneron's Ebola antibody Inmazeb as the DRC outbreak spreads. — Fierce Pharma

Outpace ended a Phase 1 ovarian cancer trial of mesothelin CAR-T OPB-101. — Endpoints

Teva will close an underutilized New Jersey plant and cut 61 jobs. — Fierce Pharma

A nonprofit revived a shelved gene therapy after Bloomsbury Genetic Therapies shut down. — STAT

Ferring / Gameto: acquisition for up to $1.3825B including milestones, upfront undisclosed; Fertilo stem cell-derived IVF tech, US Phase 3 (see The Big 3). — BioPharma Dive

Astellas / Audax Biosciences: exclusive option and licence on DAX-044, an immune-targeted IL-12 antibody-cytokine fusion; Audax funds Phase 1, terms undisclosed. — PR

Anthropic / Mithril Medicine: acquisition of the one-person, Atlas Venture-backed stealth biotech working in rare muscular dystrophy; terms undisclosed. — Endpoints

No notable private financings since yesterday.

Aclaris (ACRS): priced $50M, 7.79M shares at $3.50 plus 6.5M pre-funded warrants, TCGX, RA Capital, Invus and a large mutual fund; Leerink/Piper Sandler/Cantor/LifeSci; same-day ATI-052 (TSLP x IL-4Ra) Phase 1b showed a 45% placebo-adjusted EASI drop at day 57 (n=14, AD). — PR

No relevant academic updates since yesterday’s edition.